Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial

Feb.07.2024
Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial
Philippine newspaper Manila Standard calls for a reassessment of the country's e-cigarette law in an editorial.

The large Philippine newspaper Manila Standard recently published an editorial calling for a reassessment of the country's e-cigarette bill.


On July 25, 2022, the Republic Act No. 11900 was enacted in the Philippines with the aim of regulating the importation, sale, packaging, distribution, use, and promotion of "vaporized nicotine and non-nicotine products, as well as new tobacco products such as vape and heated tobacco products." However, in the past two years since its introduction, the law has lowered the age restriction for such products from 21 to 18 years old, lifted the ban on smoking and using heated tobacco products in public places, and allowed advertising and promotion of these products.


The law allows for the online sale of products with nicotine concentrations not exceeding 65 milligrams per milliliter (6.5%), and lowers the legal purchasing age from 21 to 18. This means that more young people will be able to use e-cigarettes as an alternative to smoking (the legal age to purchase cigarettes is 18).


The editorial argues that this law overlooks the fact that tobacco is the highest risk factor for causing deaths and disabilities in both smokers and non-smokers in 2019.


It is estimated that tobacco use was responsible for over 112,112 deaths, accounting for 27% of the total deaths in the Philippines that year.


According to researchers, 96,000 deaths (85%) are caused by smoking, while 22,000 deaths (19%) are caused by secondhand smoke. It is estimated that approximately 8 million people die prematurely every year due to cigarette smoke, which is a complex mixture of chemicals combined with aerosol particles or present in the gas phase. This has been a major health issue for several decades.


The report also noted that the main reasons why students use e-cigarettes include easy online access (32%), flavors (22%), and a perception that e-cigarettes are safer than traditional cigarettes (17%).


Editorial: The editorial asserts that e-cigarettes have not been around for a long time, and authorities are still uncertain about the long-term risks associated with their use. While the harm posed by vaping is considerably lesser than smoking, it cannot be deemed entirely harmless. This is where the problem lies. Therefore, the healthiest choice would be to abstain from smoking or vaping altogether.


The editorial also quotes health experts saying, "If someone uses e-cigarettes to quit smoking, their ultimate goal should be to eventually quit using e-cigarettes." The article further mentions that according to research, emerging data suggests a link between e-cigarettes and chronic lung diseases and asthma. Additionally, using both e-cigarettes and traditional cigarettes has also been associated with cardiovascular diseases.


In conclusion, there is not much difference between smoking and using e-cigarettes, as stated in the editorial. People generally believe that smoking is more harmful because the products are burned and smoke is inhaled into the lungs. However, research has shown that the damage caused by heating and inhaling solution vapor into the lungs is very similar to that of smoke. Based on this, the report calls for a reevaluation of the country's e-cigarette legislation.


The Manila Standard newspaper was established on February 11, 1987. It is controlled by the Romualdez political family, specifically the current Speaker of the House of Representatives, Ferdinand Martin Gomez Romualdez.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
The European Patent Office (EPO) published an appeal decision on November 17, 2026, revoking Philip Morris Products S.A.'s European nicotine pouch patent EP 3773494, covering a formulation involving free-base nicotine, ion-exchange resin and a water content of at least 15%. The decision followed an opposition and appeal brought by British American Tobacco (BAT) entity Nicoventures Trading Limited. Philip Morris withdrew its approval of the patent text during the appeal, leading the EPO to revoke the patent. A separate European patent, EP 3809884, covering the distribution of nicotine between a pouch membrane and its internal composition, had been revoked on September 24 following a challenge from another BAT entity. The patents share a 2019 priority basis, while related European divisional applications also exist.
company
Nov.18 by 2Firsts Perspectives
China’s Vape-Related Exports Rose 4.5% in Q3 2026 as 21.6% Growth in Shipments to the UK Offset a Decline in Shipments to the US
China’s Vape-Related Exports Rose 4.5% in Q3 2026 as 21.6% Growth in Shipments to the UK Offset a Decline in Shipments to the US
China's vape-related exports rose 4.5% year over year to $2.86 billion in the third quarter of 2026, led by stronger shipments to the United Kingdom as exports to the United States declined. UK-bound shipments increased 21.6%, adding $81.9 million, while US exports fell 5.2%, or $53.6 million. Growth weakened through the quarter, with September exports down 6.3% globally and 37.8% to the US. Nicotine-containing vape products accounted for more than 82% of the quarterly net increase, while device exports were nearly flat. Nine-month exports totaled $7.82 billion, up 4.0%.
DATA
Oct.26
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives